A diagnostic immunoassay based on circulating tumor‐associated autoantibodies, including the PGAM1 autoantibody, was recently established and proposed for advanced‐stage non‐small cell lung cancer (NSCLC) patients receiving PD‐1/L1 immunotherapy.[30] Thus, further studies are required to validate the predictive value of circulating PGAM1 levels for immunotherapeutic efficacy in HCC patients. This evidence concerns the gene PGAM1 and hepatocellular carcinoma.